In this issue:
GLP-1 agonists: acute pancreatitis risk
CGM vs. SMBG in type 2 diabetes
PTDM after solid organ transplantation
Tirzepatide vs. dulaglutide for type 2 diabetes: major kidney events
REIMAGINE 1–3: cagrilintidesemaglutide for type 2 diabetes
Orforglipron vs. dapagliflozin in type 2 diabetes inadequately controlled with metformin
Retatrutide (GIP, GLP-1 and glucagon receptor agonist) for inadequately controlled type 2 diabetes
1-year outcomes with semaglutide, tirzepatide and sleeve gastrectomy for obesity and type 2 diabetes
Please login below to download this issue (PDF)